Jose Conejo-Garcia
@conejo-garcia.bsky.social
Great story from Carlos Ontiveros and Tyler Curiel on the role opf PD-L2 in anti-tumor immunity in old subjects with melanoma.
PD-L1 and PD-1 blockade are often equated but biologically it is not the same and they may have different clinical applications.
rdcu.be/eQWiw
PD-L1 and PD-1 blockade are often equated but biologically it is not the same and they may have different clinical applications.
rdcu.be/eQWiw
Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling
Nature Communications - PD-L2 can bind the immune checkpoint PD-1. However, its potential as a therapeutic target for immune checkpoint blockade in cancer has not been extensively explored. Here,...
rdcu.be
November 20, 2025 at 12:18 PM
Great story from Carlos Ontiveros and Tyler Curiel on the role opf PD-L2 in anti-tumor immunity in old subjects with melanoma.
PD-L1 and PD-1 blockade are often equated but biologically it is not the same and they may have different clinical applications.
rdcu.be/eQWiw
PD-L1 and PD-1 blockade are often equated but biologically it is not the same and they may have different clinical applications.
rdcu.be/eQWiw
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization:
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
Press Releases :: Anixa Biosciences, Inc. (ANIX)
ir.anixa.com
November 17, 2025 at 1:44 PM
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization:
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
The promise of TIL therapy for glioblastoma.
Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers:
www.sciencedirect.com/science/arti...
Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers:
www.sciencedirect.com/science/arti...
The promise of TIL therapy for glioblastoma
Tumor-infiltrating lymphocyte (TIL) therapy has demonstrated efficacy in refractory melanoma and durable responses in lung cancer. Glioblastoma presen…
www.sciencedirect.com
November 14, 2025 at 12:50 AM
The promise of TIL therapy for glioblastoma.
Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers:
www.sciencedirect.com/science/arti...
Inspiring perspective from Mustafa Kharaw's team on their ongoing work to make immunotherapy effective against one of the most devastating human cancers:
www.sciencedirect.com/science/arti...
Anixa Biosciences, Inc. (ANIX), which is testing CER T cells redirected against FSHR with FSH in patients with relapsed, chemoresisatnt ovarian cancer, will participate in the upcoming Water Tower Research Fireside Chat Series (November 11, 2025, at 11:00am PT)
us06web.zoom.us/webinar/regi...
us06web.zoom.us/webinar/regi...
Welcome! You are invited to join a webinar: Fireside Chat: Anixa Biosciences, Inc. (ANIX) . After registering, you will receive a confirmation email about joining the webinar.
Please join us for a conversation with Chairman & CEO Dr. Amit Kumar, PhD, on Tuesday, November 11, 2025, at 2:00 pm ET. Our topics of discussion will cover:
• An overview of clinical development pro...
us06web.zoom.us
November 10, 2025 at 4:38 PM
Anixa Biosciences, Inc. (ANIX), which is testing CER T cells redirected against FSHR with FSH in patients with relapsed, chemoresisatnt ovarian cancer, will participate in the upcoming Water Tower Research Fireside Chat Series (November 11, 2025, at 11:00am PT)
us06web.zoom.us/webinar/regi...
us06web.zoom.us/webinar/regi...
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy | Science Translational Medicine www.science.org/doi/10.1126/...
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy
Depletion of the ER stress sensor IRE1α can reduce paclitaxel-induced peripheral neuropathy in mice.
www.science.org
November 3, 2025 at 9:28 PM
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy | Science Translational Medicine www.science.org/doi/10.1126/...
Medicine Nobel for researchers who characterized the immunobiology of regulatory T cells (previously "suppressor T cells"):
www.science.org/content/arti...
www.science.org/content/arti...
Medicine Nobel for researchers who discovered immune system's security guards
Mary Brunkow, Fred Ramsdell, Shimon Sakaguchi honored for research on ‘peripheral immune tolerance’
www.science.org
October 6, 2025 at 10:19 AM
Medicine Nobel for researchers who characterized the immunobiology of regulatory T cells (previously "suppressor T cells"):
www.science.org/content/arti...
www.science.org/content/arti...
Thanks indeed to all program officers and grant manager specialists at the NIH. I admire their resilience and commitment to keeping the NIH as the best science funding agency in the world even when tehm are under assault by the administration. It is clear who is on the side of Science and who is not
September 29, 2025 at 8:19 PM
Thanks indeed to all program officers and grant manager specialists at the NIH. I admire their resilience and commitment to keeping the NIH as the best science funding agency in the world even when tehm are under assault by the administration. It is clear who is on the side of Science and who is not
working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era url: academic.oup.com/jnci/article...
A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer ...
Abstract. Endometrial cancer is now the leading cause of gynecologic cancer death in the United States. Recognizing the urgent need to improve outcomes for
academic.oup.com
September 11, 2025 at 7:11 PM
working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era url: academic.oup.com/jnci/article...
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology:
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
August 12, 2025 at 1:44 PM
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology:
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
Immune memory shapes ovarian cancer recurrence:
Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...
Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...
Immune memory shapes ovarian cancer recurrence
Despite current progress, many patients with ovarian cancer (OC) often relapse after
therapy. In this issue of Cancer Cell, Ghisoni et al. integrate multiomic and functional
analyses to provide a road...
www.cell.com
August 11, 2025 at 4:47 PM
Immune memory shapes ovarian cancer recurrence:
Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...
Comment on the article of Ghisoni and Dangaj in Cancer Cell www.cell.com/cancer-cell/...
Dr. Robert Wenham, principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, at the Briar Club in Houston, Texas.
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
August 8, 2025 at 2:18 PM
Dr. Robert Wenham, principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will be presenting at the 13th Annual Ovarcoming Cancer Conference, being held September 18 – 19, 2025, at the Briar Club in Houston, Texas.
ir.anixa.com/press-releas...
ir.anixa.com/press-releas...
I am disappointed and alarmed that millions of Americans listen to these comments and do not see anything fundamentally wrong and indicative of a psychopathy.
August 5, 2025 at 1:54 PM
I am disappointed and alarmed that millions of Americans listen to these comments and do not see anything fundamentally wrong and indicative of a psychopathy.
This is important, among other reasons, because ICIs failed in relapsed ovarian cancers, questioning whether relapsed tumors lost immunogenicity.
Although analyses of neoantigens and TCR frequencies are ongoing, it is clear that tumors re-establish the immuno-environment (e.g., TIL patterns).
Although analyses of neoantigens and TCR frequencies are ongoing, it is clear that tumors re-establish the immuno-environment (e.g., TIL patterns).
July 31, 2025 at 4:31 PM
This is important, among other reasons, because ICIs failed in relapsed ovarian cancers, questioning whether relapsed tumors lost immunogenicity.
Although analyses of neoantigens and TCR frequencies are ongoing, it is clear that tumors re-establish the immuno-environment (e.g., TIL patterns).
Although analyses of neoantigens and TCR frequencies are ongoing, it is clear that tumors re-establish the immuno-environment (e.g., TIL patterns).
This new study from Dangaj& Ghisoni in Cancer Cell analyzed 131 matching primary/relapsed ovarian cancers, to show that the immune landscape of the original tumor is re-established in the recurrent lesion, which depends on HRD status and pre-existing TIL:myeloid niches. www.cell.com/cancer-cell/...
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer
Ghisoni et al. profile the immune landscape of 697 ovarian cancers (OCs), identifying
four immune phenotypes linked to prognosis and treatment response. The study demonstrates
that BRCA-dependent TIL:...
www.cell.com
July 31, 2025 at 3:26 PM
This new study from Dangaj& Ghisoni in Cancer Cell analyzed 131 matching primary/relapsed ovarian cancers, to show that the immune landscape of the original tumor is re-established in the recurrent lesion, which depends on HRD status and pre-existing TIL:myeloid niches. www.cell.com/cancer-cell/...
Federal government freezes $108 million in NIH funding to Duke. Apparently for racial discrimination...against white Anglos in the Deep South...this sounds like a Tarantino movie... www.dukechronicle.com/article/2025...
Federal government freezes $108 million in NIH funding to Duke, source tells The Chronicle
The freeze follows two federal investigations launched Monday by the Trump administration into Duke University and Duke Health, alleging “systemic racial discrimination” and violations of the Civil Ri...
www.dukechronicle.com
July 31, 2025 at 11:14 AM
Federal government freezes $108 million in NIH funding to Duke. Apparently for racial discrimination...against white Anglos in the Deep South...this sounds like a Tarantino movie... www.dukechronicle.com/article/2025...
In this new study, Aaron Ring and colleagues demonstrate the importance of antibody responses on the effectiveness of patients with cancer treated with ICI. As for treatment naive tumors, these are autoandibodies thsat in most cases do not cause autoimmunity:
rdcu.be/exGyT
rdcu.be/exGyT
Humoral determinants of checkpoint immunotherapy
Nature - Rapid extracellular antibody profiling reveals a contribution of autoantibodies to the effectiveness of checkpoint immunotherapy for cancer.
rdcu.be
July 24, 2025 at 6:11 PM
In this new study, Aaron Ring and colleagues demonstrate the importance of antibody responses on the effectiveness of patients with cancer treated with ICI. As for treatment naive tumors, these are autoandibodies thsat in most cases do not cause autoimmunity:
rdcu.be/exGyT
rdcu.be/exGyT
There is at least some attention from the press to the devastation of the scientific enterprise that is going on...
Trump Seeks to Cut Basic Scientific Research by Roughly One-Third, Report Shows www.nytimes.com/2025/07/10/s...
Trump Seeks to Cut Basic Scientific Research by Roughly One-Third, Report Shows www.nytimes.com/2025/07/10/s...
Trump Seeks to Cut Basic Scientific Research by Roughly One-Third, Report Shows
www.nytimes.com
July 10, 2025 at 3:28 PM
There is at least some attention from the press to the devastation of the scientific enterprise that is going on...
Trump Seeks to Cut Basic Scientific Research by Roughly One-Third, Report Shows www.nytimes.com/2025/07/10/s...
Trump Seeks to Cut Basic Scientific Research by Roughly One-Third, Report Shows www.nytimes.com/2025/07/10/s...
Improving lung cancer tumor infiltrating lymphocytes (TILs) manufacturing - Cytotherapy www.isct-cytotherapy.org/article/S146...
Improving lung cancer tumor infiltrating lymphocytes (TILs) manufacturing
The successful treatment of melanoma using autologous in-vitro expanded tumor infiltrating
lymphocytes (TILs) has sparked clinical trials for the assessment of TILs efficacy
against other cancers, inc...
www.isct-cytotherapy.org
July 9, 2025 at 3:18 PM
Improving lung cancer tumor infiltrating lymphocytes (TILs) manufacturing - Cytotherapy www.isct-cytotherapy.org/article/S146...
In immunology, for instance, experiments can only be done in vivo to capture the complex interactions of multiple cell types, cytokines and chemokines. No computer will predict immune subsets and mediators that we do not fully understand yet.
July 8, 2025 at 12:53 PM
In immunology, for instance, experiments can only be done in vivo to capture the complex interactions of multiple cell types, cytokines and chemokines. No computer will predict immune subsets and mediators that we do not fully understand yet.
NIH announces end to funding for animal-only studies. This is potentially catastrophic. www.drugdiscoverytrends.com/nih-announce...
NIH announces end to funding for animal-only studies - Drug Discovery and Development
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
www.drugdiscoverytrends.com
July 8, 2025 at 12:49 PM
NIH announces end to funding for animal-only studies. This is potentially catastrophic. www.drugdiscoverytrends.com/nih-announce...
Zelig Eshhar, leading cancer researcher and immunologist, and the father of CAR T cells, dies at 84:
www.timesofisrael.com/zelig-eshhar...
www.timesofisrael.com/zelig-eshhar...
Zelig Eshhar, leading cancer researcher and immunologist, dies at 84
Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for $12 billion in 2017
www.timesofisrael.com
July 7, 2025 at 7:10 PM
Zelig Eshhar, leading cancer researcher and immunologist, and the father of CAR T cells, dies at 84:
www.timesofisrael.com/zelig-eshhar...
www.timesofisrael.com/zelig-eshhar...
Great article from Tao wang in Nature Cancer:
The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data
www.nature.com/articles/s43...
The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data
www.nature.com/articles/s43...
Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes - Nature Cancer
Song et al. developed a computational tool to profile binding pairs between tumor-derived antigens and antibodies from high-throughput B cell receptor sequencing data, predicting response to immune-ch...
www.nature.com
June 30, 2025 at 10:39 PM
Great article from Tao wang in Nature Cancer:
The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data
www.nature.com/articles/s43...
The abundance of tumor antigen-targeting antibodies is predictive of ICI response. Plus a new computational method to predict binding between antibodies and antigens that can be scaled to high-throughput sequencing data
www.nature.com/articles/s43...
Reposted by Jose Conejo-Garcia
Building Better Immunotherapy: Using a method spearheaded by led by José Ramón Conejo-Garcia, MD, PhD, and Scott Antonia, MD, PhD (pictured here), immune cells are being engineered to find and attack cancer tumors.
🔗: medschool.duke.edu/stories/buil...
#AcademicSky #MedSky #Immunobiology
🔗: medschool.duke.edu/stories/buil...
#AcademicSky #MedSky #Immunobiology
June 26, 2025 at 11:44 AM
Building Better Immunotherapy: Using a method spearheaded by led by José Ramón Conejo-Garcia, MD, PhD, and Scott Antonia, MD, PhD (pictured here), immune cells are being engineered to find and attack cancer tumors.
🔗: medschool.duke.edu/stories/buil...
#AcademicSky #MedSky #Immunobiology
🔗: medschool.duke.edu/stories/buil...
#AcademicSky #MedSky #Immunobiology
They did not need to delay the progress of biomedical research for many years, ruining the life of thousands of valuable people in the process, to find that people mostly work in government because they believe in the mission of the agency. Very efficiently for what they earn
June 26, 2025 at 3:53 PM
They did not need to delay the progress of biomedical research for many years, ruining the life of thousands of valuable people in the process, to find that people mostly work in government because they believe in the mission of the agency. Very efficiently for what they earn
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial. No dose-limiting toxicities were observed in the third cohort.
The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies.
ir.anixa.com/press-releas...
The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies.
ir.anixa.com/press-releas...
Press Releases :: Anixa Biosciences, Inc. (ANIX)
ir.anixa.com
June 23, 2025 at 1:40 PM
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial. No dose-limiting toxicities were observed in the third cohort.
The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies.
ir.anixa.com/press-releas...
The trial is enrolling women with recurrent ovarian cancer who have progressed after two prior therapies.
ir.anixa.com/press-releas...